{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"090-012-186-842-786","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"090-012-186-842-786"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8902,"type":"PATENT","title":"University of Tokyo Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":20983,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8217,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search applicants and owners = \"Univ Tokyo\", \"Univ Tokyo NOT metropolitan\", \"Tokyo Univ\",\"University of Tokyo NOT metropolitan\", \"Tokyo Univ\".
Select more for logical variants
Add to collection
Total patent: 13934
Search applicants and owners = \"Univ Tokyo\", \"Univ Tokyo NOT metropolitan\", \"Tokyo Univ\",\"University of Tokyo NOT metropolitan\", \"Tokyo Univ\".
Select more for logical variants
Add to collection
Total patent: 13934
(a) a polypeptide comprising the amino acid sequence of SEQ ID NO: 4;
(b) a polypeptide that comprises the amino acid sequence of SEQ ID NO: 4 or a sequence having at least about 80% homology to SEQ ID NO: 4;
(c) a polypeptide comprising an amino acid sequence of SEQ ID NO: 4, wherein one or more amino acid(s) in the sequence is modified by deletion, addition, insertion and/or substitution by other amino acids, and the number of mutation is typically no more than 35% of all amino acids, and wherein the polypeptide has a biological activity equivalent to a polypeptide consisting of the amino acid sequence of any one of SEQ ID NO: 4; and
(d) a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 3, wherein the polypeptide has a biological activity equivalent to a polypeptide consisting of the amino acid sequence of SEQ ID NO: 4."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["An isolated polynucleotide encoding the polypeptide of claim 1."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["A vector comprising the polynucleotide of claim 2."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["A host cell harboring the polynucleotide of claim 2 or the vector comprising the polynucleotide."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["A method for producing the polypeptide of claim 1, said method comprising the steps of:
(a) culturing the host cell harboring the polynucleotide encoding the polypeptide of claim 1 or the vector comprising the polynucleotide;
(b) allowing the host cell to express the polypeptide; and
(c) collecting the expressed polypeptide."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["An antibody binding to the polypeptide of claim 1, wherein the antibody binds to antigenic determinant comprising the amino acid sequence from 304 to 588 of SEQ ID NO: 4."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["A polynucleotide that is complementary to the polynucleotide of SEQ ID NO: 3 or to the complementary strand thereof and that comprises at least 15 nucleotides, wherein the polynucleotide hybridizes nucleotide sequence comprising of positions from 988 to 1842 of SEQ ID NO:3."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["An antisense polynucleotide or small interfering RNA against the polynucleotide comprising nucleotide sequence of SEQ ID NO: 3, wherein the target sequence of the antisense polynucleotide or small interfering RNA comprises a nucleotide sequence selected from positions from 988 to 1842 of SEQ ID NO: 3."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["A method for diagnosing bladder cancer, said method comprising the steps of:
(a) detecting the expression level of the gene encoding the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136 in a biological sample; and
(b) relating an elevation of the expression level to the bladder cancer."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 9, wherein the expression level is detected by any one of the method selected from the group consisting of:
(a) detecting the mRNA encoding the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136,
(b) detecting the protein comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136, and
(c) detecting the biological activity of the protein comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["A method of screening for a compound for treating or preventing bladder cancer, said method comprising the steps of:
(a) contacting a test compound with a polypeptide selected from the group consisting of:(i) a polypeptide comprising the amino acid sequence of selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136;(ii) a polypeptide that comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136 or a sequence having at least about 80% homology to said sequence; and(iii) a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 129, 131, 133 and 135,wherein the polypeptide has a biological activity equivalent to a polypeptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136;
(b) detecting the binding activity between the polypeptide and the test compound; and
(c) selecting a compound that binds to the polypeptide."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["A method of screening for a compound for treating or preventing bladder cancer, said method comprising the steps of:
(a) contacting a test compound with a polypeptide selected from the group consisting of:(i) a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136;(ii) a polypeptide that comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136 or a sequence having at least about 80% homology to said sequence; and(iii) a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 129, 131, 133 and 135, wherein the polypeptide has a biological activity equivalent to a polypeptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136;
(b) detecting the biological activity of the polypeptide of step (a); and
(c) selecting a compound that suppresses the biological activity of the polypeptide in comparison with the biological activity detected in the absence of the test compound."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 12, wherein the biological activity is cell-proliferating activity."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["A method of screening for a compound for treating or preventing bladder cancer, said method comprising the steps of:
(a) contacting a test compound with a cell expressing one or more polynucleotides comprising the nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 129, 131, 133 and 135; and
(b) selecting a compound that reduces the expression level of one or more polynucleotides comprising the nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 129, 131, 133 and 135 in comparison with the expression level detected in the absence of the test compound."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 14, wherein the cell is bladder cancer cell."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["A method of screening for a compound for treating or preventing bladder cancer, said method comprising the steps of:
(a) contacting a test compound with a cell into which a vector comprising the transcriptional regulatory region of one or more marker genes and a reporter gene that is expressed under the control of the transcriptional regulatory region has been introduced, wherein the one or more marker genes comprise any one of the nucleotide sequence of SEQ ID NOs: 1, 3, 5, 129, 131, 133 and 135,
(b) measuring the expression level or activity of said reporter gene; and
(c) selecting a compound that reduces the expression level or activity of said reporter gene as compared to the expression level or activity of said reporter gene detected in the absence of the test compound."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["A composition for treating or preventing bladder cancer, said composition comprising a pharmaceutically effective amount of an antisense polynucleotide or small interfering RNA against a polynucleotide and pharmaceutically acceptable carrier, wherein the polynucleotide encodes a polypeptide selected from the group consisting of:
(a) a polypeptide that comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136;
(b) a polypeptide that comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136 in which one or more amino acids are substituted, deleted, inserted and/or added and that has a biological activity equivalent to the polypeptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4 6, 130, 132, 134 and 136; and
(c) a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 129, 131, 133 and 135, wherein the polypeptide has a biological activity equivalent to a polypeptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136as an active ingredient, and a pharmaceutically acceptable carrier."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The composition of claim 17, wherein said small interfering RNA comprises the nucleotide sequence of SEQ ID NO: 21, 25 or 144 as the target sequence."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["The composition of claim 18, said siRNA has the general formula 5'-[A]-[B]-[A']-3', wherein [A] is a ribonucleotide sequence corresponding to the nucleotide sequence of SEQ ID NO: 21, 25 or 144, [B] is a ribonucleotide sequence consisting of 3 to 23 nucleotides, and [A'] is a ribonucleotide sequence consisting of the complementary sequence of [A]."],"number":19,"annotation":false,"title":false,"claim":true},{"lines":["The composition of claim 17, wherein said composition comprises a transfection-enhancing agent."],"number":20,"annotation":false,"title":false,"claim":true},{"lines":["A composition for treating or preventing bladder cancer, said composition comprising a pharmaceutically effective amount of an antibody against a polypeptide selected from the group consisting of:
(a) a polypeptide that comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136;
(b) a polypeptide that comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136 in which one or more amino acids are substituted, deleted, inserted and/or added and that has a biological activity equivalent to the polypeptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136; and
(c) a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 129, 131, 133 and 135 wherein the polypeptide has a biological activity equivalent to the polypeptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136as an active ingredient, and a pharmaceutically acceptable carrier."],"number":21,"annotation":false,"title":false,"claim":true},{"lines":["A composition for treating or preventing bladder cancer, said composition comprising a pharmaceutically effective amount of the compound selected by the method of any one of claims 11 to 16 as an active ingredient, and a pharmaceutically acceptable carrier."],"number":22,"annotation":false,"title":false,"claim":true},{"lines":["A method for treating or preventing bladder cancer, said method comprising the step of administering a pharmaceutically effective amount of an antisense polynucleotide, or small interfering RNA against a polynucleotide encoding a polypeptide selected from the group consisting of:
(i) a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136;
(ii) a polypeptide that comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136 in which one or more amino acids are substituted, deleted, inserted and/or added and that has a biological activity equivalent to the polypeptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136; and
(iii) a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 129, 131, 133 and 135 wherein the polypeptide has a biological activity equivalent to a polypeptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136."],"number":23,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 23, wherein said siRNA comprises the nucleotide sequence of SEQ ID NO: 21, 25 or 144 as the target sequence."],"number":24,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 24, said siRNA has the general formula 5'-[A]-[B]-[A']-3', wherein [A] is a ribonucleotide sequence corresponding to the nucleotide sequence of SEQ ID NO: 21, 25 or 144, [B] is a ribonucleotide sequence consisting of 3 to 23 nucleotides, and [A'] is a ribonucleotide sequence consisting of the complementary sequence of [A]."],"number":25,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 25, wherein said composition comprises a transfection-enhancing agent."],"number":26,"annotation":false,"title":false,"claim":true},{"lines":["A method for treating or preventing bladder cancer, said method comprising the step of administering a pharmaceutically effective amount of an antibody against a polypeptide selected from the group consisting of:
(a) a polypeptide that comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136;
(b) a polypeptide that comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136 in which one or more amino acids are substituted, deleted, inserted and/or added and that has a biological activity equivalent to the polypeptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136; and
(c) a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 129, 131, 133 and 135, wherein the polypeptide has a biological activity equivalent to the polypeptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136."],"number":27,"annotation":false,"title":false,"claim":true},{"lines":["A method for treating or preventing bladder cancer, said method comprising the step of administering a pharmaceutically effective amount of a compound selected by the method of any one of claims 11 to 16."],"number":28,"annotation":false,"title":false,"claim":true},{"lines":["A method for treating or preventing bladder cancer, said method comprising the step of administering a pharmaceutically effective amount of a polypeptide selected from the group consisting of (a)-(c), or a polynucleotide encoding the polypeptide:
(a) a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136 or fragment thereof;
(b) a polypeptide that comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136 in which one or more amino acids are substituted, deleted, inserted and/or added and that has a biological activity equivalent to the polypeptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136;
(c) a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 129, 131, 133 and 135, wherein the polypeptide has a biological activity equivalent to the polypeptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136, or fragment thereof."],"number":29,"annotation":false,"title":false,"claim":true},{"lines":["A method for inducing an anti tumor immunity, said method comprising the step of contacting a polypeptide selected from the group consisting of (a)-(c) with antigen presenting cells, or introducing a polynucleotide encoding the polypeptide or a vector comprising the polynucleotide to antigen presenting cells:
(a) a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136 or fragment thereof;
(b) a polypeptide that comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136 in which one or more amino acids are substituted, deleted, inserted and/or added and that has a biological activity equivalent to the polypeptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136;
(c) a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 129, 131, 133 and 135, wherein the polypeptide has a biological activity equivalent to the polypeptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136, or fragment thereof."],"number":30,"annotation":false,"title":false,"claim":true},{"lines":["The method for inducing an anti tumor immunity of claim 30, wherein the method further comprising the step of administering the antigen presenting cells to a subject."],"number":31,"annotation":false,"title":false,"claim":true},{"lines":["A pharmaceutical composition for treating or preventing bladder cancer, said composition comprising a pharmaceutically effective amount of polypeptide selected from the group of (a)-(c), or a polynucleotide encoding the polypeptide:
(a) a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136 or fragment thereof;
(b) a polypeptide that comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136 in which one or more amino acids are substituted, deleted, inserted and/or added and that has a biological activity equivalent to the polypeptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136;
(c) a polypeptide encoded by a polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of the nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 129, 131, 133 and 135, wherein the polypeptide has a biological activity equivalent to the polypeptide consisting of the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136, or fragment thereofas an active ingredient, and a pharmaceutically acceptable carrier."],"number":32,"annotation":false,"title":false,"claim":true},{"lines":["The pharmaceutical composition of claim 32, wherein the polynucleotide is incorporated in an expression vector."],"number":33,"annotation":false,"title":false,"claim":true},{"lines":["A diagnostic agent for diagnosing a bladder cancer, wherein the reagent comprises an oligonucleotide that hybridizes to the polynucleotide encoding the polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 130, 132, 134 and 136, or an antibody that binds to said polypeptide."],"number":34,"annotation":false,"title":false,"claim":true},{"lines":["A double-stranded molecule comprising a sense strand and an antisense strand, wherein the sense strand comprises a ribonucleotide sequence corresponding to SEQ ID NO: 21, 25 or 144, and wherein the antisense strand comprises a ribonucleotide sequence which is complementary to said sense strand, wherein said sense strand and said antisense strand hybridize to each other to form said double-stranded molecule, and wherein said double-stranded molecule, when introduced into a cell expressing at least any one of the gene consisting of nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 129, 131, 133 and 135, inhibits expression of said gene."],"number":35,"annotation":false,"title":false,"claim":true},{"lines":["The double-stranded molecule of claim 35, wherein said sense strand comprises from about 19 to about 25 contiguous nucleotides from any one of the nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 129, 131, 133 and 135."],"number":36,"annotation":false,"title":false,"claim":true},{"lines":["The double-stranded molecule of claim 35, wherein said sense strand consists of the ribonucleotide sequence corresponding to SEQ ID NO: 21, 25 or 144."],"number":37,"annotation":false,"title":false,"claim":true},{"lines":["The double-stranded molecule of claim 35, wherein a single ribonucleotide transcript comprises the sense strand and the antisense strand, said double-stranded molecule further comprising a single-stranded ribonucleotide sequence linking said sense strand and said antisense strand."],"number":38,"annotation":false,"title":false,"claim":true},{"lines":["A vector encoding the double-stranded molecule of claim 35."],"number":39,"annotation":false,"title":false,"claim":true},{"lines":["The vector of claim 39, wherein the vector encodes a transcript having a secondary structure, wherein the transcript comprises the sense strand and the antisense strand."],"number":40,"annotation":false,"title":false,"claim":true},{"lines":["The vector of claim 39, wherein the transcript further comprises a single-stranded ribonucleotide sequence linking said sense strand and said antisense strand."],"number":41,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}